New drugs for hyperprolactinaemia.
In 1976 we heralded the introduction of bromocriptine (Parlodel-Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia. Now two new drugs are available for treating hyperprolactinaemia; cabergoline (Dostinex-Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide (Norprolac-Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?
D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D000077465:Cabergoline; D002986:Clinical Trials as Topic; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D006727:Hormone Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*
D000634:Aminoquinolines; D004873:Ergolines; D006727:Hormone Antagonists; D001971:Bromocriptine; C046650:quinagolide; D000077465:Cabergoline